Serum Bone Turnover Markers (PINP and ICTP) for the Early Detection of Bone Metastases in Patients With Prostate Cancer: A Longitudinal Approach

Journal of Urology

Volumn 178, Issue 3, 2007, Pages 849-853

  Koopmans, N ^a   de Jong, I J ^a   Breeuwsma, A J ^a   van der Veer, E ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

biological markers; bone and bones; neoplasm metastasis; prostatic neoplasms

Indexed keywords

AMINO TERMINAL PROCOLLAGEN PROPEPTIDE OF TYPE 1 COLLAGEN; AMINO TERMINAL TELOPEPTIDE; ANTIANDROGEN; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; PYRIDINOLINE; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; CARCINOMA; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; ORCHIECTOMY; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34547659662     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.05.029     Document Type: Article

References (20)

1. Rosenthal D.I. Radiologic diagnosis of bone metastases. Cancer 80 (1997) 1595
2. Jung K., Lein M., Stephan C., Von H.K., Semjonow A., Sinha P., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111 (2004) 783
3. O'Sullivan J.M., and Cook G.J. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 46 (2002) 152
4. Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E., and Delmas P.D. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82 (2000) 858
5. Koga H., Naito S., Koto S., Sakamoto N., Nakashima M., Yamasaki T., et al. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39 (1999) 1
6. Koizumi M., Yonese J., Fukui I., and Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87 (2001) 348
7. Tamada T., Sone T., Tomomitsu T., Jo Y., Tanaka H., and Fukunaga M. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19 (2001) 45
8. Kylmala T., Tammela T.L., Risteli L., Risteli J., Kontturi M., and Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71 (1995) 1061
9. Noguchi M., and Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 166 (2001) 1106
10. Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., and Stratte P.T. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 (2000) 181
11. Miyaji Y., Saika T., Yamamoto Y., Kusaka N., Arata R., Ebara S., et al. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 64 (2004) 128
12. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154
13. Greenspan S.L., Coates P., Sereika S.M., Nelson J.B., Trump D.L., and Resnick N.M. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90 (2005) 6410
14. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol 157 (1997) 439
15. Ramankulov A., Lein M., Kristiansen G., Loening S.A., and Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67 (2007) 330
16. Lein M., Wirth M., Miller K., Eickenberg H.U., Weissbach L., Schmidt K., et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol (2007) epub ahead of print.
17. Garnero P., Ferreras M., Karsdal M.A., Nicamhlaoibh R., Risteli J., Borel O., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18 (2003) 859
18. Li B.Y., Liao X.B., Fujito A., Thrasher J.B., Shen F.Y., and Xu P.Y. Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. Asian J Androl 9 (2007) 41
19. Brasso K., Christensen I.J., Johansen J.S., Teisner B., Garnero P., Price P.A., et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66 (2006) 503
20. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879